HIV Scientific Papers
Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311) [abstract].
2019
Open Forum Infect Dis.
Emu B, DeJesus E, Berhe M, et al.
6 (suppl 2):S303. Proceedings of IDWeek, 2019.
Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311).
2019
Emu B, DeJesus E, Berhe M, et al.
Poster #661 presented at: IDWeek; October 2-6, 2019; Washington, DC, USA.
Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals [abstract].
2019
Top Antivir Med.
Emu B, Lalezari J, Kumar P, et al.
"27(suppl 1):179s. Proceedings of the 2019 Conference on Retroviruses and Opportunistic Infections. "
Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals.
2019
Emu B, Lalezari J, Kumar P, et al.
Poster #485 presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, Washington, USA.
The use of EQ-5D Visual Analog Scale (EQ-VAS) in disease areas where EQ-5D is insensitive to changes in the disease status: The case of lipodystrophy [abstract].
2019
Value Health.
Tremblay G, de Chantal M, Forsythe A, Marsolais C.
22(suppl 3):S901. Proceedings of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2019.